Abstract: The present invention relates to soluble and stable anti-VEGF imunobinders comprising CDRs from rabbit monoclonal antibodies. Said antibodies are designed for the diagnosis and/or treatment of VEGF-mediated disorders. The hybridomas, nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.

Abstract: The present invention relates to an isolated multispecific antibody comprising a first domain specifically binding TNF? and a second domain specifically binding IL-17A and, optionally, a third domain specifically binding human serum albumin. The present invention furthermore relates to an isolated antibody which specifically binds human IL-17A, Additionally, the present invention further relates to methods of use of said antibodies, pharmaceutical compositions and methods of use thereof, and a kit comprising said antibodies. The present invention also relates to a nucleic acid comprising a nucleotide sequence encoding said antibodies, a vector comprising said nucleic acid, a host cell comprising said nucleic acid or said vector, and a method of producing said antibodies.

Abstract: An industrial switching device prevents a false indication of an open electrical circuit when contacts within the switching device are welded shut. Under normal operation, an actuator is selectively moved between a first position and a second position to reciprocally move a plunger to open and close the contacts. The actuator includes an indicator of whether the switching device is in the “ON” or “OFF” state. When the contacts are welded shut, a plunger engagement section interlocks with an actuator engagement section to prevent the actuator from moving from the “ON” position to the “OFF” position. A crossbar on the plunger engagement section embeds in the actuator engagement section to prevent the actuator from sliding over the plunger. A side member on the plunger engagement section prevents the actuator from sliding around the plunger.

Abstract: The present invention relates to soluble and stable anti-VEGF imunobinders comprising CDRs from rabbit monoclonal antibodies. Said antibodies are designed for the diagnosis and/or treatment of VEGF-mediated disorders. The hybridomas, nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.

Abstract: The present invention relates to a multispecific antibody comprising at least one CD137 binding domain and at least one PDL1 binding domain, and pharmaceutical compositions and methods of use thereof. The present invention further relates to a nucleic acid encoding said multispecific antibody, a vector comprising said nucleic acid, a host cell comprising said nucleic acid or said vector, and a method of producing said multispecific antibody.

Abstract: This invention relates to a hetero-dimeric multi-specific format of multiple antibody variable domains comprising a core of two split variable domain pairs wherein both variable light domains and the two cognate variable heavy domains are positioned in tandem on two separate protein chains, respectively, and wherein one of said variable domain pairs is specific for human serum albumin and the other said variable domain pair is specific for human CD3.

Abstract: This invention relates to novel hetero-dimeric multi-specific format of multiple antibody variable domains comprising a core of two split variable domain pairs wherein both variable light domains and the two cognate variable heavy domains are positioned in tandem on two separate protein chains, respectively.

Abstract: A switching device for industrial equipment having at least one pair of contacts includes a transfer member rotatably mounted in the switching device. The transfer member is configured to receive a first force applied to the switching device in a first direction and to receive a second force applied to the switching device in a second direction. A rocker arm, rotatably mounted in the switching device, engages the transfer member to receive the first force over a first angle of rotation and to receive the second force over a second angle of rotation. The second angle of rotation is less than the first angle of rotation. A lever arm is pivotally mounted within the switching device. The lever arm engages the rocker arm to move between an Off position and an On position, and a plunger is actuated by the lever arm to selectively open and close the contacts.

Abstract: The present invention relates to an universal antibody acceptor framework and to methods for grafting non-human antibodies, e.g., rabbit antibodies, using a universal antibody acceptor framework. Antibodies generated by the methods of the invention are useful in a variety of diagnostic and therapeutic applications.

Abstract: The present invention relates to a pharmaceutical composition comprising a first multispecific antibody (MA1) comprising one binding domain, which specifically binds to CD137 (CD137-BD), and one binding domain, which specifically binds to PDL1 (PDL1-BD); a second multispecific antibody (MA2) comprising at least one binding domain, which specifically binds to a tumor cell associated antigen (TAA-BD), and one binding domain, which specifically binds to CD3 (CD3-BD); and a pharmaceutically acceptable carrier. The present invention further relates to a kit comprising said first multispecific antibody MAl and said second multispecific antibody MA2. The present invention further relates to the use as well as to methods of use of said pharmaceutical composition or said kit.

Abstract: The present invention relates to novel antibody variable domain combinations with advantageous properties.

Abstract: The present invention relates to novel antibody frameworks with advantageous properties.

Abstract: The present invention relates to a multispecific antibody comprising two antibody-based binding domains, which specifically binds to mesothelin (MSLN-BD); and at least one antibody-based binding domain, which specifically binds to CD3 (CD3-BD); wherein said multispecific antibody does not comprise an immunoglobulin Fc region polypeptide, and wherein each of said MSLN-BD binds to mesothelin (MSLN) with a monovalent dissociation constant (KD) in the range of from 0.5 to 20 nM, when measured by SPR. The present invention further relates to nucleic acid sequence(s) encoding said multispecific antibody, vector(s) comprising aid nucleic acid sequence(s), host cell(s) comprising said nucleic acid sequence(s) or said vector(s), and a method of producing said multispecific antibody. Additionally, the present invention relates to pharmaceutical compositions comprising said multispecific antibody and methods of use thereof.

Abstract: The present invention relates to a multispecific antibody comprising at least one CD137 binding domain and at least one PDL1 binding domain, and pharmaceutical compositions and methods of use thereof. The present invention further relates to a nucleic acid encoding said multispecific antibody, a vector comprising said nucleic acid, a host cell comprising said nucleic acid or said vector, and a method of producing said multispecific antibody.

Abstract: The present invention relates to particularly stable and soluble scFv antibodies and Fab fragments specific for TNF, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNF, and low immunogenicity. The antibodies are designed for the diagnosis and/or treatment of TNF-mediated disorders. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of the antibodies in medicine are also described.

Abstract: The present invention is an industrial switching device which prevents a false indication of an open electrical circuit when contacts within the switching device are welded shut. Under normal operation, an actuator is selectively moved between a first position and a second position to reciprocally move a plunger to open and close the contacts. The actuator includes an indicator of whether the switching device is in the “ON” or “OFF” state. When the contacts are welded shut, a plunger engagement section interlocks with an actuator engagement section to prevent the actuator from moving from the “ON” position to the “OFF” position. A crossbar on the plunger engagement section embeds in the actuator engagement section to prevent the actuator from sliding over the plunger. A side member on the plunger engagement section prevents the actuator from sliding around the plunger.

Abstract: The present invention relates to a multispecific antibody comprising at least one domain specifically binding to a tumor-associated immune checkpoint antigen with low affinity, and at least one domain specifically binding to a tumor-associated antigen (TAA), and pharmaceutical compositions and methods of use thereof.

Abstract: The present invention relates to novel antibodies that are specific for human CD3, in particular for the CD3? domain.

Abstract: This invention relates to novel hetero-dimeric multi-specific format of multiple antibody variable domains comprising a core of two split variable domain pairs wherein both variable light domains and the two cognate variable heavy domains are positioned in tandem on two separate protein chains, respectively.

Abstract: A switch device includes a lock component and a crossbar. The crossbar is configured to open or close electric contacts. The crossbar includes a lock receiving section for receiving the lock component after the switch device is turned to an ON position for a period of time. The lock component is disengaged from the lock receiving section after the period of time to allow the crossbar jump upwards to close the electric contacts quickly.